Abstract:Background: For any drug molecule, it is mandatory to pass the drug approval process of the concerned regulatory authority, before being marketed. The Food and Drug Administration (FDA), throughout the year, approves several new drugs for safety and efficacy. In addition to new drug approvals, FDA also works on improving access to generic drugs, aimed to lower the cost of drugs for patients and improve access to treatments. In the year 2022 twelve new drug therapies were approved for managing varying cancers. Methods: This manuscript is focused to describe the pharmacological aspects including therapeutic uses, mechanisms of actions, pharmacokinetics, adverse effects, doses, indication for special cases, contraindications, etc., of novel FDA-approved anticancer drug therapies in the year 2022. Result: FDA has approved about 29% (11 out of 37) novel drug therapies for varying types of cancers such as lung cancer, breast cancer, prostate cancer, melanoma, leukemia, etc. The Center for Drug Evaluation and Research CDER has reported that 90% of these anticancer drugs (e.g. Adagrasib, Futibatinib, Mirvetuximabsoravtansine-gynx, Mosunetuzumab-axb, Nivolumab and relatlimab-rmbw, Olutasidenib, Pacritinib, Tebentafusp-tebn, Teclistamab-cqyv, and Tremelimumab-actl) as orphan drugs and recommended to treat rare or uncommon cancers such as non-small cell lung cancer, metastatic intrahepatic cholangio-carcinoma, epithelial ovarian cancer, follicular lymphoma, metastatic melanoma, metastatic uveal melanoma, etc. CDER has identified six anticancer drugs (e.g. Lutetium (177Lu)vipivotidetetraxetan, Mirvetuximabsoravtansine-gynx, Mosunetuzumab-axb, Nivolumab and relatlimab-rmbw, Tebentafusp-tebn, Teclistamab-cqyv) as first-in-class drugs i.e. drugs having different mechanisms of action from the already existing ones. The newly approved anticancer drugs shall provide more efficient treatment options for cancer patients. Three FDA-approved anticancer drugs in the year 2023 are also briefly described in the manuscript. Conclusion: This manuscript, describing the pharmacological aspects of eleven anticancer novel drug therapies approved by the FDA, shall serve as a helpful document for cancer patients, concerned academicians, researchers, and clinicians, especially oncologists.

Synthetic Approaches to the New Drugs Approved During 2022

New drug approvals for 2021: Synthesis and clinical applications

A comprehensive review of new small molecule drugs approved by the FDA in 2022: Advance and prospect

New drug approvals for 2020: Synthesis and clinical applications

Synthesis and clinical application of new drugs approved by FDA in 2023

A comprehensive review of small molecule drugs approved by the FDA in 2023: Advances and prospects

The mechanism of action and chemical synthesis of FDA newly approved drug molecules

New drug approvals for 2019: Synthesis and clinical applications

Small molecule anticancer drugs approved during 2021-2022: Synthesis and clinical applications

Novel drugs approved by the EMA, the FDA, and the MHRA in 2023: A year in review

A year in pharmacology: new drugs approved by the US Food and Drug Administration in 2023

The Pharmaceutical Industry in 2020. An Analysis of FDA Drug Approvals from the Perspective of Molecules

Recent and anticipated novel drug approvals (3Q 2024 through 2Q 2025)

A comprehensive review of discovery and development of drugs discovered from 2020-2022

An Expedition on Synthetic Methodology of FDA-approved Anticancer Drugs (2018-2021)

Metabolism of new drug modalities research advances - 2023 year in review

Pharmacological profile of novel anti-cancer drugs approved by USFDA in 2022: A Review

New Approved Drugs Appearing in the Pharmaceutical Market in 2022 Featuring Fragments of Tailor-Made Amino Acids and Fluorine

The Pharmaceutical Industry in 2023: An Analysis of FDA Drug Approvals from the Perspective of Molecules

A Decade of FDA-Approved Drugs (2010–2019): Trends and Future Directions

Recent and anticipated novel drug approvals for 2024